Skip to main content

Drug Interactions between anagrelide and mexiletine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

mexiletine anagrelide

Applies to: mexiletine and anagrelide

MONITOR: Theoretically, coadministration with drugs that are inhibitors of CYP450 1A2 may increase the plasma concentrations of anagrelide, which is a substrate of the isoenzyme.

MANAGEMENT: Clinicians should recognize the potential for interaction with drugs that inhibit CYP450 1A2 and monitor for evidence of anagrelide toxicities during coadministration. Since platelet reduction from anagrelide therapy is dose-related, thrombocytopenia may occur due to reduced clearance of anagrelide and may be a sign of overdosage. Patients should also be monitored for cardiovascular adverse effects such as tachycardia, palpitations, hypotension, edema, and congestive heart failure.

References

  1. (2001) "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer